SEARCH

SEARCH BY CITATION

References

  • Bataille, R., Chappard, D. & Basle, M.F. (1996) Quantifiable excess of bone resorption in monoclonal gammopathy is an early symptom of malignancy: a prospective study of 87 bone biopsies. Blood, 87, 47624769.
  • Corso, A., Arcaini, L., Mangiacavalli, S., Astori, C., Orlandi, E., Lorenzi, A., Passamonti, F., Klersy, C., Pascutto, C., Canevari-Sciorati, A. & Lazzarino, M. (2001) Biochemical markers of bone disease in asymptomatic early stage multiple myeloma. A study on their role in identifying high-risk patients. Haematologica, 86, 394398.
  • Diamond, T., Levy, S., Smith, A., Day, P. & Manoharan, A. (2001) Non-invasive markers of bone turnover and plasma cytokines differ in osteoporotic patients with multiple myeloma and monoclonal gammopathies of undetermined significance. Internal Medicine Journal, 31, 272278.
  • Garnero, P., Sornay-Rendu, E., Claustrat, B. & Delmas, P.D. (2000) Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. Journal of Bone and Mineral Research, 15, 15261536.
  • Jakob, C., Zavrski, I., Heider, U., Brux, B., Eucker, J., Langelotz, C., Sinha, P., Possinger, K. & Sezer, O. (2002) Bone resorption parameters [carboxy-terminal telopeptide of type-I collagen (ICTP), amino-terminal collagen type-I telopeptide (NTx), and deoxypyridinoline(Dpd)] in MGUS and multiple myeloma. European Journal of Haematology, 69, 3742.
  • Oyajobi, B.O., Franchin, G., Williams, P.J., Pulkrabek, D., Gupta, A., Munoz, S., Grubbs, B., Zhao, M., Chen, D., Sherry, B. & Mundy, G.R. (2003) Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease. Blood, 102, 311319.
  • Pecherstorfer, M., Seibel, M.J., Woitge, H.W., Horn, E., Schuster, J., Neuda, J., Sagaster, P., Kohn, H., Bayer, P., Thiebaud, D., Ludwig, H. (1997) Bone resorption in multiple myeloma and in monoclonal gammopathy of undetermined significance: quantification by urinary pyridinium cross-links of collagen. Blood, 90, 37433750.
  • Sezer, O., Heider, U., Zavrski, I., Kuhne, C.A. & Hofbauer, L.C. (2003) RANK ligand and osteoprotegerin in myeloma bone disease. Blood, 101, 20942098.
  • Terpos, E., Szydlo, R., Apperley, J.F., Hatjiharissi, E., Politou, M., Meletis, J., Viniou, N., Yataganas, X., Goldman, J.M. & Rahemtulla, A. (2003a) Soluble receptor activator of nuclear factor kappa-B ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood, 102, 10641069.
  • Terpos, E., Politou, M., Szydlo, R., Goldman, J.M., Apperley J.F. & Rahemtulla, A. (2003b) Serum levels of macrophage inflammatory protein-1 alpha (MIP-1α) correlate with the extent of bone disease and survival in patients with multiple myeloma. British Journal of Haematology, 123, 106109.
  • Tian, E., Zhan, F., Walker, R., Rasmussen, E., Ma, Y., Barlogie, B. & Shaughnessy, J.D. Jr (2003) The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. New England Journal of Medicine, 349, 24832494.
  • Vejlgaard, T., Abildgaard, N., Jans, H., Nielsen, J.L. & Heickendorff, L. (1997) Abnormal bone turnover in monoclonal gammopathy of undetermined significance: analyses of type I collagen telopeptide, osteocalcin, bone-specific alkaline phosphatase and propeptides of type I and type III procollagens. European Journal of Haematology, 58, 104108.